新型心脏保护液对心肌保护作用的实验研究
|
摘要
心脏保护液目前已应用于心脏外科各种体外循环下心脏直视手术和心脏移植手术中,能够为心脏提供有效的心肌保护,极大地促进了心脏外科的发展。根据目前国内外在心脏手术中对心脏保护液的选择及对心脏保护液的研究进展,我们研制了新型的心脏保护液,并通过离体鼠心Langendorff模型及小型猪体外循环心脏直视手术模型将它和目前广泛应用于心脏手术中的HTK心脏保护液及St·ThomasⅡ心脏保护液进行了对比研究,旨在进一步研究心脏保护液的作用机制及最佳成份以提高心肌保护效果。
本研究分为两部分,第一部分为通过建立离体鼠心Langendorff模型进行离体鼠心灌注-冷存-再灌注实验,模拟心脏移植手术对心脏供体获取、保存及移植过程中心脏保护液对心肌的保护。实验从血流动力学(冠脉流量、心率、左心室收缩峰压、左心室舒张期末压、左心室发展压,心脏作功指数、左心室收缩期压力最大上升速率、左心室舒张期压力最大下降速率)、心肌酶(肌酸激酶同工酶及心肌肌钙蛋白T)、心肌含水率、冠状动脉内皮细胞功能(一氧化氮含量、内皮素-1含量)、抗过氧化反应(超氧化物歧化酶、丙二醛)、心肌三磷酸腺苷和心肌病理结构(光镜、电镜)等方面对新型心脏保护液、HTK保护液和ST·ThomasⅡ保护液的心脏保存效果进行评价。结果显示,新型心脏保护液在各方面均优于或等同于HTK保护液和ST·ThomasⅡ保护液的心脏保存效果。
第二部分为通过建立小型猪体外循环手术模型进行小型猪体外循环下心脏直视手术实验,模拟临床体外循环下心脏直视手术过程中心脏保护液对心肌的保护。实验从血流动力学、心肌酶、心肌含水率、冠状动脉内皮细胞功能、抗过氧化反应和凋亡心肌细胞检测(凋亡细胞形态学观察、凋亡细胞阳性率、心肌细胞凋亡相关基因蛋白表达)等方面对新型心脏保护液、HTK保护液和ST·ThomasⅡ保护液的心脏保护效果进行评价。结果显示,新型心脏保护液在各方面均优于或等同于HTK保护液和ST·ThomasⅡ保护液的心肌保护效果。
两部分实验分别建立了用于心脏保护液研究的离体及在体动物实验模型,初步检验了新型心脏保护液对大鼠及小型猪的心肌保护作用并得到了较为满意的实验结果,为下一步对心脏保护液的实验研究打下基础。
Cardioplegia solution is now used in a variety of open heart surgery under cardiopulmonary bypass and heart transplant surgery; the solution can provide effective myocardial protection, which greatly promoted the development of cardiac surgery. Based on the current seletion of cardioplegia solution during the operation and the research of myocardial protection at home and abroad, we have developed a new cardiaoplegia solution and make a comparative reseach with the HTK solution and St·ThomasⅡsolution which is widely used in cardiac surgery through the isolated rat heart Langendorff model and mini-pig open heart surgery under cardiopulmonary bypass model. The reseach is designed to further study the mechanism and the best ingredients of cardilplegia solution to enhance the myocardial protective effect.
The research is divided into two parts; the first part is to conduct the isolated rat heart perfusion - cold storage - reperfusion experiment through the establishment of isolated rat heart Langendorff model to simulate the myocardial protection of the cardioplegia solution during the heart transplant surgery on the heart donor acquisition, preservation and transplantation processes. The experiment evaluate the effect of heart preservation of new cardioplegia solution, HTK solution and ST·ThomasⅡsolution from the hemodynamics (coronary flow, heart rate, left ventricular peak systolic pressure, left ventricular end-diastolic pressure, left ventricular developed pressure, cardiac work index, maximal rate of left ventricular systolic pressure, maximal rate of left ventricular diastolic pressure), myocardial enzymes (creatine kinase MB and cardiac troponin T), myocardial water content, coronary endothelial function (nitric oxide, endothelin-1), antiperoxidation (superoxide dismutase, malondialdehyde), myocardial adenosine triphosphate and myocardial pathological structure (light microscopy, electron microscopy). The results showed that the myocardial preservation effect of new cardioplegia solution was superior to or equivalent to HTK solution and ST·ThomasⅡsolution in all respects.
The second part is to conduct the mini-pig open heart operation experiment through the establishment of mini-pig open heart surgery under cardiopulmonary bypass model to simulate the myocardial protection of the cardioplegia solution during the open heart surgery under cardiopulmonary bypass. The experiment evaluate the effect of myocardial protection of new cardioplegia solution, HTK solution and ST·ThomasⅡsolution from the hemodynamics, myocardial enzymes, myocardial water content, coronary endothelial function, antiperoxidation, and apoptosis in cardiomyocytes (apoptotic cell morphology, apoptotic cell positive rate and protein expression of apoptosis-related gene). The results showed that the myocardial protective effect of new cardioplegia solution was superior to or equivalent to HTK solution and ST·ThomasⅡsolution in all respects.
Two experiments set up the in-vitro and in-vivo animal models to research the cardioplegia solution, tested the myocardial protective effect of isolated rat heart and mini-pig and got satisfied results. It will make a basis for followed research of cardioplegia solution.
本研究分为两部分,第一部分为通过建立离体鼠心Langendorff模型进行离体鼠心灌注-冷存-再灌注实验,模拟心脏移植手术对心脏供体获取、保存及移植过程中心脏保护液对心肌的保护。实验从血流动力学(冠脉流量、心率、左心室收缩峰压、左心室舒张期末压、左心室发展压,心脏作功指数、左心室收缩期压力最大上升速率、左心室舒张期压力最大下降速率)、心肌酶(肌酸激酶同工酶及心肌肌钙蛋白T)、心肌含水率、冠状动脉内皮细胞功能(一氧化氮含量、内皮素-1含量)、抗过氧化反应(超氧化物歧化酶、丙二醛)、心肌三磷酸腺苷和心肌病理结构(光镜、电镜)等方面对新型心脏保护液、HTK保护液和ST·ThomasⅡ保护液的心脏保存效果进行评价。结果显示,新型心脏保护液在各方面均优于或等同于HTK保护液和ST·ThomasⅡ保护液的心脏保存效果。
第二部分为通过建立小型猪体外循环手术模型进行小型猪体外循环下心脏直视手术实验,模拟临床体外循环下心脏直视手术过程中心脏保护液对心肌的保护。实验从血流动力学、心肌酶、心肌含水率、冠状动脉内皮细胞功能、抗过氧化反应和凋亡心肌细胞检测(凋亡细胞形态学观察、凋亡细胞阳性率、心肌细胞凋亡相关基因蛋白表达)等方面对新型心脏保护液、HTK保护液和ST·ThomasⅡ保护液的心脏保护效果进行评价。结果显示,新型心脏保护液在各方面均优于或等同于HTK保护液和ST·ThomasⅡ保护液的心肌保护效果。
两部分实验分别建立了用于心脏保护液研究的离体及在体动物实验模型,初步检验了新型心脏保护液对大鼠及小型猪的心肌保护作用并得到了较为满意的实验结果,为下一步对心脏保护液的实验研究打下基础。
Cardioplegia solution is now used in a variety of open heart surgery under cardiopulmonary bypass and heart transplant surgery; the solution can provide effective myocardial protection, which greatly promoted the development of cardiac surgery. Based on the current seletion of cardioplegia solution during the operation and the research of myocardial protection at home and abroad, we have developed a new cardiaoplegia solution and make a comparative reseach with the HTK solution and St·ThomasⅡsolution which is widely used in cardiac surgery through the isolated rat heart Langendorff model and mini-pig open heart surgery under cardiopulmonary bypass model. The reseach is designed to further study the mechanism and the best ingredients of cardilplegia solution to enhance the myocardial protective effect.
The research is divided into two parts; the first part is to conduct the isolated rat heart perfusion - cold storage - reperfusion experiment through the establishment of isolated rat heart Langendorff model to simulate the myocardial protection of the cardioplegia solution during the heart transplant surgery on the heart donor acquisition, preservation and transplantation processes. The experiment evaluate the effect of heart preservation of new cardioplegia solution, HTK solution and ST·ThomasⅡsolution from the hemodynamics (coronary flow, heart rate, left ventricular peak systolic pressure, left ventricular end-diastolic pressure, left ventricular developed pressure, cardiac work index, maximal rate of left ventricular systolic pressure, maximal rate of left ventricular diastolic pressure), myocardial enzymes (creatine kinase MB and cardiac troponin T), myocardial water content, coronary endothelial function (nitric oxide, endothelin-1), antiperoxidation (superoxide dismutase, malondialdehyde), myocardial adenosine triphosphate and myocardial pathological structure (light microscopy, electron microscopy). The results showed that the myocardial preservation effect of new cardioplegia solution was superior to or equivalent to HTK solution and ST·ThomasⅡsolution in all respects.
The second part is to conduct the mini-pig open heart operation experiment through the establishment of mini-pig open heart surgery under cardiopulmonary bypass model to simulate the myocardial protection of the cardioplegia solution during the open heart surgery under cardiopulmonary bypass. The experiment evaluate the effect of myocardial protection of new cardioplegia solution, HTK solution and ST·ThomasⅡsolution from the hemodynamics, myocardial enzymes, myocardial water content, coronary endothelial function, antiperoxidation, and apoptosis in cardiomyocytes (apoptotic cell morphology, apoptotic cell positive rate and protein expression of apoptosis-related gene). The results showed that the myocardial protective effect of new cardioplegia solution was superior to or equivalent to HTK solution and ST·ThomasⅡsolution in all respects.
Two experiments set up the in-vitro and in-vivo animal models to research the cardioplegia solution, tested the myocardial protective effect of isolated rat heart and mini-pig and got satisfied results. It will make a basis for followed research of cardioplegia solution.
引文
[1] Barner HB. Blood cardioplegia: a review and comparison with crystalloid cardioplegia.Ann Thorac Surg 1991, 52: 1354-1367.
[2] Follette DM, Steed DL, Foglia RP, Fey KH, Buckberg GD. Reduction of postischemic myocardial damage by maintaining arrest during initial reperfusion. Surg Forum. 1977, 28: 281-283
[3] Beckberg GD. A proposed "solution" to the cardioplegic controversy. J Thorac Cardiovasc Surg 1979, 77: 803-815
[4] Fremes SE, Weisel RD, Mickle DA, Ivanov J, Madonik MM, Seawright SJ, Houle S, McLaughlin PR, Baird RJ Myocardial metabolism and ventricular function following cold potassium cardioplegia. J Thorac Cardiovasc Surg. 1985, 89: 531-546
[5] Demmy TL, Biddle JS, Bennett LE, Walls JT, Schmaltz RA, Curtis JJ. Transplantation. Organ preservation solutions in heart transplantation--patterns of usage and related survival.1997, 63: 262-269
[6] Shriakura R,Matsuda H,Nakata S, et al、Preservation of Cadavar Heart with Belzer UW Solution :24- hour Storage system for asphyxiated canine hearts. J Eur Surg Res. 1990, 22: 197-205
[7] Chambers DJ, Hearse DJ. Cardioplegia and surgical ischemia. Sperelalkis N,Kurachi Y, Terzic A, Cohen MV, eds. Heart physiology and pathophysiology. San Diego: Academic Press. 2001, 887～925
[8] Attwell D, Cohen I, Eisner D, et al. The steady–state TTX-sensitive (window) sodium current in cardiac Purkinje fibres. Pflugers Arch. 1979, 379: 137-142
[9] Bretschneider HJ. Myocardial protection. Thorac Cadiovasc Surg. 1980, 28: 295-302
[10] Houischer M, Groenewoud AF.Current status of the HTK solution of Bretschneider in organ preservation. Transplantation Proceedings. 1991, 23: 2334-2337
[11] Hachida M, Ookado A, Nonoyama M, et al. Effect ofHTK solution for myocardial preservation. J Cardiovasc Surg. 1996, 37: 269-274
[12] Chocron S, Kaili D, Yan Y, Toubin G, Latini L, Clement F, Viel JF, Etievent JP. Intermediate lukewarm (20℃) antegrade intermittent blood cardioplegia compared with cold and warm blood cardioplegia. J Thorac Cardiovasc Surg. 2000, 119: 610-616
[13] Buckberg GD. Oxygenated cardioplegia: blood is a many splendored thing. Ann Thorac Surg. 1990, 50: 175-177
[14] Minatoya K, Okabayashi H, Shimada I, Tanabe A, Nishina T, Nandate K, Kunihiro M.Intermittent antegrade warm blood cardioplegia for CABG: extended interval of cardioplegia.Ann Thorac Surg. 2000, 69: 74-76
[15] Langendorff O. Untersuchungen am uberlebenden saugetierherz. Arch Ges Physiol. 1895, 61: 291-316
[16] Porter WT. A new method for the study of the isolated mammalian heart. Am J Physiol. 1898, 1: 511-517
[17] Legtenberg RJ,Houston RJ,Smits P.Hemodynamic changes caused by glibenclamide in isolated, working, erythrocyte perfused rat heart.Adv Exp Med Biol. 1999, 471: 257-263
[18] Sutherland FJ, Hearse DJ. The isolated blood and perfusion fluid perfused heart. Pharmacol Res. 2000, 41: 613-627
[19] Suzer O, Suzer A, Aykac Z. Direct cardiac effects in isolated perfused rat hearts measured at increasing concentrations of morphine, alfentanil, fentanyl, ketamine, etomidate, thiopentone, midazolam and propofol. Eur Janaesthesiol. 1998,15: 480-485
[20] Hannon J P, Bossone C A, Wade C E. Normal physiological values for conscious pigs used in biomedical research. Lab Anim Sci. 1990, 40: 293-298
[21] Li D, Ren B H, Shen Y, et al. A Swine model for long-term evaluation of prosthetic heart valves. ANZ J Surg, 2007. 77: 654-658
[22] Lomholt M, Nielsen S L, Hansen S B, et al. Differential tension between secondary and primary mitral chordae in an acute in-vivo porcine model. J Heart Valve Dis. 2002, 11: 337-345
[23] Smerup M, Pedersen T F, Nyboe C, et al. A long-term porcine model for evaluation of prosthetic heart valves. Heart Surg Forum. 2004, 7: 259-264
[24] Wittnich C, Belanger M P, Wallen W J, et al. A long-term stable normothermic cardiopulmonary bypass model in neonatal swine. J Surg Res. 2001, 101: 176-182
[25]柳德斌.自体心包在三尖瓣成形手术中的实验研究: [博士学位论文].北京:清华大学医学院,2009
[26] Li D, Ren B H, Shen Y, et al. A Swine model for long-term evaluation of prosthetic heart valves. ANZ J Surg. 2007, 77: 654-658
[27] Duke E. C., Vincent K. H., Wen C., Maceo B. Studies in the physiology of cardiopulmonary bypass using a swine model: Swine as Models in Biomedical Research. Swindle M. M., Moddy D. C., Phillips L. C. Iowa State University Press. 1992:185-197
[28] Hubert M B, Salazkin I, Desjardins J, et al. Cardiopulmonary bypass surgery in swine: a research model. J Exp Anim Sci. 2003, 43: 135-149
[29] Boschert K, Flecknell P A, Fosse R T, et al. Ketamine and its use in the pig. Recommendations of the Consensus meeting on Ketamine Anaesthesia in Pigs, Bergen 1994. Ketamine Consensus Working Group. Lab Anim, 1996, 30(3): 209-219
[30]卿恩明.心血管手术麻醉学.北京:人民军医出版社, 2006:56
[31] Strom J, Haggmark S, Reiz S, et al. Cardiovascular effects of pentobarbital in pigs, and the lack of response to naloxone in pentobarbital induced circulatory failure. Acta Anaesthesiol Scand. 1987, 31: 413-416
[32] Skovsted P, Sapthavichaikul S. The effects of isoflurane on arterial pressure, pulse rate, autonomic nervous activity, and barostatic reflexes. Can Anaesth Soc J. 1977, 24: 304-314
[33] Adams H A. [S-(+)-ketamine. Circulatory interactions during total intravenous anesthesia and analgesia-sedation]. Anaesthesist. 1997, 46: 1081-1087
[34] White P F. The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg. 2002, 94: 577-585
[35]钟佛添,刘初生,巫国勇等.供者心脏热缺血后收缩力、三磷酸腺苷、超微结构的关系.中国胸心血管外科临床杂志.2000,7:28-310
[36] Belzet FO, Southard JH. Principles of solid-organ preservation by cole storage.Transplantation. 1988, 45: 673-675
[37] Weiss M, Piwnica A, Bloch G et al. Experimental evaluation of Celsior, a new heart preservation solution. Eur J Cardiothorac Surg, 1994, 8: 207-213
[38] Bauza G, Lima L, Le Moyec L, Gandjbakhch I, Eugène M. 12-hour preservation of rat hearts with "fabrique d'implants et d'instruments" or University of Wisconsin oxygenated microperfused cardioplegic solution. Transplant Proc. 1996, 28: 2899
[39] Yeh CH, Lin YM, Wu YC, et al. Notric oxide attenuates cardiomyocytic apoptosis via diminished mitochondrialcomplex I up-regulation from cardiac ischemia-reperfusion injury under cardiopulmonary bypass[J]. J Thorac Cardiovasc Surg. 2004, 128: 180
[40] Bouma P, Ferdinandy P, Sipkema P et al. Nitric oxide is an important determinant of coronary flow in the isolated blood perfused rat heart. Basic Res Cardiol. 1992,87: 570-584
[41] Mizuno A, Baretti R, Buckberg GD, et al. Endothelial stunning and myocyte recovery after referfusion of jeopardized muscle: a role of L-arginine blood cardioplegia. J Thorac Cardiovasc Surg. 1997,113: 379
[42] Pabla R, Buda AJ, Flynn DM et al. Nitric oxide attenuates neutrophil mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res.1996, 78: 65-72
[43] Nonami Y. The role of nitric oxide in cardiac ischemia-reperfusion injury. Jpn Circ J. 1997, 61:119-132
[44] Amrani M,Gray CC,Smolenski RT et al. The effect of L-Arginine on myocardial recovery after cardioplegic arrest and ischemia under moderate and deep hypothermia. Circulation, 1997, supple II 96: 274- 279
[45] Kown MH, Lijkwan MA, Jahncke CL, et al. L-Arginine polymers enhance coronary flowand reduce oxidative stress following cardiac transplantation in rats. J Thorac Cardiovasc Surg. 2003, 126: 1065
[46] Pernow J,Uriuda Y,Wang QD et al. The protective effect of L-arginine on myocardial injury and endothelial function following ischaemia and reperfusion in the pig. Eur Heart J.1994,15: 1712-1719
[47] Amrani M, Chester AH,Jayakumar B, et al. L-arginine reverses low coronary reflow and enhances postischaemic recovery of cardiac mechanical function. Cardiovasc Res. 1995, 30: 200-204
[48] Kronon MT, Allen BS,Halldorsson A et al. Dose dependency of L-arginine in neonatal myocardial protection: the nitric oxide paradox. J Thorac Cardiovasc Surg. 1999,118:655-64
[49] Soos P, Andrasi T, Buhmann V, et al. Myocardial protection after systemic application of L- arginine during reperfusion. J Cardiovasc Pharmacol. 2004, 43: 782
[50] Albes M, Baumgartel I, Rohde R et al. Influence of dextrans on cardiac preservation in an extracorporeal rat heart model. Eur Surg Res. 1995, 27: 406-410
[51] Le-Gal YM,Scott T, Prabhakaran VM et al. Heart-lung protection from ischemic injury during 8 hour hypothermic preservation. Acta Biomed Ateneo Parmense. 1994, 65:181-198
[52] Sumimoto R, Linden SL,Southerd JH, et al .A comparison of hiStidine lactobionate and UW solution In 48-hour dog liver preservation. J Transplantation. 1992, 54: 610-621
[53] Gschwend JE,Continuous In situ cold perfusion with HTK solution In nephron spring surgery for renal tumor , J Urology,1997, 156: 1307-1311
[54] Pedro J,Wilson J,Donald GM,et al. The role of cardioplegic solution buffering In myocardial protection. J Thorac Cardiovasc Surg. 1985, 89: 689-699
[55] Wilson GJ,Axford-Gatley RA,Bush BC,et al .European versus North American cardioplehia Comparsion of Bretschmeiders and Roes cardioplegic solutions in a canine model of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990, 38: 4-10
[56] Fedelesova M,Ziegelhoffer A,Krause EC,et al. Effect of exogenous adenosine triphosphate on the metabolic State of the excised hypothemic dog heart. J Circ Res. 1960, 24: 617-627
[57]郭为农,吾柏铭.腺苷的心血管病生理作用及其临床应用.国外医学心血管分册. 1993,20: 91-94
[58] Lee HT, Emala CW. Characterization of adenosine receptors in human kidney proximal tubule (HK-2) cells. Exp Nephrol. 2002, 10: 383-392
[59] Mangoni ME, Barrere-Lemaire S. Adenosine receptors, heart rate, and cardioprotection. Cardiovasc Res. 2004, 62: 447-449
[60] Janin Y, Qian YZ, Hoag JB, et al. Pharmacologic preconditioning with monophosphoryl lipid A is abolished by 5-hydroxydecanoate, a specific inhibitor of the K(ATP) channel. J Cardiovasc Pharmacol. 1998, 32: 337-342
[61] Spinale FG. Cellular and molecular therapeutic targets for treatment of contractile dysfunction after cardioplegic arrest. Ann Thorac Surg. 1999, 68: 1934-1938
[62] Dobson GP, Jones MW. Adenosine and lidocaine: A new concept in nondepolarizing surgical myocardial arrest, protection, and preservation. J Thorac Cardiovasc Surg. 2004, 127: 794-797.
[63] De Jong JW,Meer P,Loon H, et al. Adenosisne as an adjunct to potassitum cardioplegia:effect on function,energy metabolism,and electrophysiology. J Thora Cardiovasc Surg. 1990,100: 445-454
[64] Dowey JM,Liu CS,Thornton JD. Adinosine and anti-infarct effects of preconditioning. J Cardiovasc Res. 1993, 27: 3-8
[65] Boudjema K, Vanfulik TM,Lindell SL, et al. Effect of oxidized and reduced glutathione in heart preservation. J Transplantation ,1990, 50: 948-952
[66]马欣,李玉成.谷氨酰胺与心肌缺血再灌注损伤.中国动脉硬化杂志. 2007,15: 873-875
[67] Westagy S. Organ dysfunction after cardiopulmonary bypass: a systemic inflammatory reaction initiated by the extracorporeal cricuit. 1987, 13:89-95
[68] Khogali SE.Harper AA.Lyall JA.Rennie MJ Effects of L-glutamine on post-ischaemic cardiac function:protection and rescue 1998, 30: 819-827
[69] Stottrup NB.Kristiansen SB.Lofgren B.Hansen BF Kimose HH Botker HE L-gluta-mate and glutamine improve haemodynamic function and restore myocardial glycogen content during postischaemic reperfusion:A radiactive tracer study in the rat isolated beart 2006, 30: 1099-1103
[70] Liu J, Marchase RB, Chatham JC. Glutamine-induced protection of isolated rat beart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protedin O-GlcNAc levels. 2007, 43:177-185
[71] Ingeborg R, Kober M, Obermaur RP, et al. Comparison of the solutions ofBretshneider,St.Thomas’Hospital and the national institutes of health for cardioplegic protection during moderate hypothermic arrest. Eur Surg Res. 1998, 30:243-251
[72] Hacida M, Ookado A, Nonoyama M, et al. Effect of HTK solution for myocardial preservation. J Cardiovasc Surg. 1996, 37:269-274
[73] Murphy E.Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. CircRes, 2004, 94: 7-14
[74] Garlid K D,Paucek P.Yarov-arovoy T, et a1.Cardioprotective effect of diazoxide and itsinteraction with mitochondrial ATP-sensitive K+ channels.CircRes. 1997, 8l: 1072-1079
[75] Holmuhamedov EL, Wang L, Terzic A. ATP-sensitive K+channel openers prevent Ca2+ overload in rat cardiac mitochondria. J Physiol. 1999, 519: 347-360
[76] Laclau MN, Boudina S, Thambo JB, et al. Cardioprotection by ischemic preconditioning preserves mitochondrial function and functional coupling between adenine nucleotide translocase and creatinekinase. J Mol Cell Cardiol. 2001, 33: 947-956
[77] Babcock DF, Herrington J, Goodwin PC, et al. Mitochondrial participation in the intracellular Ca2+ network. J Cell Biol. 1997, 136: 833-844
[78] Ozcan C, Bienengraeber M, Petras P, et al. Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress atreoxygenation. Am J Physiol Heart Circ Physiol. 2002, 282: 531-539
[79] Wang Y, Ashraf M. Role of protein kinase C in mitochondrial KATP channel mediated protection against Ca2+ overload injury in rat myocardium. Circ Res. 1999, 84: 1156-1165
[80] Halestrap AP. Regulation of mitochondrial metabolism through changes in matrix volume. Biochem Soc Trans. 1994, 22: 522-529
[81]兰锡纯,冯卓荣等.心脏血管外科学.北京:人民卫生出版社,2002.422
[82]杭燕南,庄心良,蒋豪,徐慧芳等.当代麻醉学.上海:上海科学技术出版社,2002:484
[83] Hosenpud JD, Bennett LE, Keck BM, et al. The registry of the International Society for Heart and Lung Transplantation: sixteenth official report. J Heart Lung Transplant. 1999, 18: 611-626
[84]孙晨光,夏求明,等.异体原位心脏移植(附6例报道).中华器官移植杂志. 2000, 21: 237-239
[85] J.Wei, C.Y Chang, Y C Chuang, et al. Successful Heart Transplantation After 13 Hours of Donor Heart. Transplantation Proceedings. 2005, 37: 2253-2254
[86] Wheeldon D. Thoracic organ preservation. Perfusion. 1991, 6: 191-202
[87] Wahlers T, Cremer J, Fleguth HC, et al. Dornor related variables and 30-day mortality after heart transplantation. J Heart Lung Transplant. 1991, 10: 22-27
[88] Del Rizzo DF, Menkis AH, Pfungfelder PW, et al. The role of donor age and ischemic time on survival following orthotopic heart transplantation. J Heart Lung Transplant. 1999, 18: 310-319
[89] Young JB, Naftel DC, Bourge RC, et al. Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multinstitutional report. The transplant cardiologists research Database Group. J Heart Lung Transplant. 1994, 13: 353-365
[90] Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretrasnplantation risk factors for death after heart transplantation: a multi-institutional study. The transplant cardiologistsresearch Database Group. J Heart Lung Transplant. 1993, 12: 549-562
[91] Fernandez J, Aranda J, Mabbot S, et al. Overseas procurement of donor hearts: ischemic time effect of postoperative outcomes. Transplant Proc. 2001, 33: 3803-3804
[92] Brigand EM, Bergin PJ, Rosenfelt FL, et al. Successful long-term outcome with prolonged ischemic in cardiac allografts. J Heart Lung Transplant. 1995, 14: 845-940
[93] Jahania MS, Sanchez JA, Narayan P, et al. Heart preservation for transplation principles and strategies. Ann Thorac Surg. 1999. 68: 1983-1987
[94] Buckberg GD. Update on current techniques of myocardial protection. Ann Thorac Surg. 1995. 60: 805-814
[95] Menasche PF, Groussect C, Peynet J, et al. Improved recovery of heart transplants with a specific kit of preservation solution. J Thorac Cardiovasc Surg. 1993. 105: 353-363
[96] Kevelaitis E, Peynet J, Mousa C, et al. Preconditioning by mitochondria ATP-sensentive potassium channel opener: an effective approach for improving the preservation of heart transplants. Circulation. 1999. 100(19 Supplement):345-350
[97] Shyu KG, Kuan PL, Cheng JJ, et al. Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting. Am Heart J. 1998, 135: 862-870
[98] Kawahto K, Mohara J, Misawa Y, et al. Assessment of the myocardial protective effect of antegrade warm blood cardioplegia by measuring the release of biochemical markers. Surg-Today. 1999, 29: 322-329
[99] Klaver MJ, Buckingham MG, Rich GF. Lidocaine attenuates cytokine-induced cell injury in endothelial and vascular smooth muscle cells. Anesth Analg. 2003, 97: 465-470
[100] Klaver MJ, Buckingham MG, Rich GF. Isoflurane pretreatment has immediate anddelayed protective effects against cytokine-induced injury in endothelial and vascularsmooth muscle cells.Anesthesiology. 2003, 99: 896-903
[101] Lopez JR , Jahangir R , Jahangir A , et al.Potassium channel openers prevent potassium-induced calciumloading of cardiac cells:possible implications in cardioplegia.J Thorac Cardiovasc Surg.1996;112:820–31.
[102] Plachinta RV, de Klaver MJ, Hayes JK, et al.The protective effect of protein kinase C and adenosine triphosphate-sensitive potassium channel agonists against inflammation in rat endothelium and vascular smooth muscle in vitro and in vivo.Anesth Analg. 2004;99:556-61
[103]王翠梅,曹红,戴体俊.线粒体敏感性ATP钾通道不参与异丙酚预处理的心肌保护.中国药理学通报2003,19(10):1155-9
[104] Beresewicz A,Maczewski M,Duda M. Effect of classic preconditioning and diazoxide on endothelial function and O2- and NO generation in the post-ischemic guinea-pig heart.Cardiovascular Research. 2004, 63, 118-129
[105] Cohen NM,Wises RM,Wechsler AS,et al. Elective cardiac arrest with a hyperpolarizing adenosine triphosphate-sensitive potassium channel opener. J ThoracCardiovasc Surg. 1993, 106: 317-328
[106] Lawton JS, Harrington GC, Allen CT, et al. Myocardial protection with pinacidil cardioplegia in the blood-perfused heart. Ann Thorac Surg.1996, 61: 1680–1688
[107] Lawton JS,Hsia PW,Allen CT,et al.Myocardial protection in the acutely injured heart: hyperpolarizing versus depolarizing hypothermic cardioplegia. J Thorac CardiovascSurg. 1997, 113: 567–575
[108] Jilkina O, Kuzio B, Grover GJ, et al. Sarcolemmal and mitochondrial effects of a KATP opener, P-1075, in"polarized" and "depolarized" Langendorff-perfused rat hearts. Biochim Biophys Acta. 2003, 8: 39-50
[109] Jiang C, Mochizuki S, Poole-Wilson PA, et al. Effect of lemakalim on action potentials, intracellular calcium, and contraction in guinea pig and human cardiac myocytes. Cardiovasc Res. 1994, 28: 851–857
[110] Garlid KD, Paucek P, Yarov-Yarovoy V, et al. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+channels. : Possible mechanism of cardioprotection. Circ Res. 1997, 81: 1072-1082
[111]张凯伦,杨运海,胡志伟等.含二氮嗪停搏液对豚鼠心肌电生理的影响.中华胸心血管外科杂志. 2004,20:44-46
[112] Kajstura J, Cheng W, Reiss K,et al. Apoptosis and Necrotic myocyte cell deaths are in rats. Lab Invest. 1996, 74: 86-107
[113] Freude B, Masters TN, Robicsek F, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol, 2000, 32: 197-208
[114] McCully JD, Wakiyama H, Cowan DB, et al. Diazoxide amelioration of myocardial injury and mitochondrial damage during cardiac surgery. Ann Thorac Surg. 2002, 74: 2138-2146
[115] Oltvai Z N, Milliman C L, Korsmeyer S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993, 74: 609 - 619
[116] Ichinose M, Yonemochi H, Sato T, et al. Diazoxide triggers cardioprotection against apoptosis induced by oxidative stress. Am J Physiol. 2003, 284: 2235-2241
[117] Akao M, Ohler A, OpRourke B, et al. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res. 2001, 88: 1267-1275
[118] Daugas E , Susin SA , Zamzami N , et al. Mitochondrio2nuclear translocation of AIF in apoptosis and necrosis. FASEB J. 2000, 14: 729-739
[119] Sperelakis N, Sunagawa M, Nakamura M. Electrogenesis of the resting potential. Heartphysiology and pathophysiology. San Diego: Academic Press, 2001: 175-198
[120] Opie LH. Channels, pumps, and exchangers. The heart: physiology and metabolism. New York: Raven Press, 1991: 67-101
[121] Sperelalkis N, Kurachi Y, Terzic A, Cohen MV. Heart physiology and pathophysiology. San Diego: Academic Press, 2001, 887-925
[122] Attwell D, Cohen I, Eisner D, et al. The steady–state TTX-sensitive (window) sodium current in cardiac Purkinje fibres. Pflugers Arch, 1979, 379: 137-142
[123] Snabaitis AK, Chambers DJ. Long-term myocardial preservation: beneficial and additive effects of polarized arrest (Na+-channel blockade), Na+/H+-exchange inhibition, and Na+/K+-cotransport inhibition combined with calciumdesensitization. Transplation. 1999, 68: 1444-1453
[124] Walgama OV, Shattock MJ, Chambers DJ. Myocardial arrest and protection: dual effect of a K-channel opener and Na-channel blocker as an alternative to hyperkalemia. J Mol Cell Cardiol. 2000, 32: 41-53
[125] Snabaitis AK, Shattock MJ, Chambers DJ. Comparison of polarized and depolarizedarrest in the isolated rat heart for long-term preservation. Circulation. 1997, 96: 3148-3156
[126] Cohen NM, Wises RM, Wechsler AS, et al. Elective cardiac arrest with a hyperpolarizing adenosine triphosphate-sensitive potassium channel opener. J Thorac Cardiovasc Surg. 1993,106: 317-328
[127] Jiang C, Mochizuki S, Poole-Wilson PA, et al. Effect of lemakalim on action potentials intracellular calcium, and contraction in guinea pig and human cardiac myocytes. Cardiovasc Res. 1994, 28: 851–857
[128] Dorman BH, Hebbar L, Hinton RB, et al. Preservation of myocyte contractile function after hypothermic cardioplegic arrest by activation of ATP-sensitive potassium channels. Circulation. 1997, 96: 2376-2384
[129] Dorman BH, Hebbar L, Clair MJ, et al. Potassium channel opener augmented cardioplegia: protection of myocyte contractility with chronic left ventricular dysfunction. Circulation.1997, 96: 253-2259
[130] Sugimoto S, Puddu PE, Monti FF, et al. Pretreatment with the adenosine triphosphate-sensitive potassium channel opener nicorandil and improved myocardial protection during high potassium cardioplegic hypoxia. J Thorac Cardiovasc Surg,1994, 108: 455-466
[131] Walgama OV, Shattock MJ, Chambers DJ. Efficacy of a KATP channel opener to induce myocardial arrest: species differences. J Mol Cell Cardiol. 2000, 32: A40-41
[132] Galinanes M, Shattock MJ, Hearse DJ. Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia. Cardiovasc Res.1992, 26: 1063–1068
[133] He GW. Coronary endothelial function in open heart surgery. Clin Exp Pharmacol Physiol. 1997, 24: 955-957
[134] He GW. Potassium channel opener in cardioplegia may restore coronary endothelial function. Ann Thorac Surg. 1998, 66: 1318-1322
[135] Holmuhamedov EL, Jovanovic S, Dzeja PP, et al. Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function. Am J Physiol. 1998, 275: H1567-1576
[136] Baines CP, Liu GS, Birincioglu M, et al. Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. Am J Physiol. 1999, 276: H1361-1368
[137] Toyoda Y, Levitsky S, McCully JD. Opening of mitochondrial ATP-sensitive potassium channels enhances cardioplegicprotection. Ann Thorac Surg. 2001, 71: 1281-1289
[138] Pieper GM, Gross GJ. Anti-free-radical and neutrophil-modulating properties of nitrovasoditator, nicorandil. Cardiovase Drugs Ther. 1992, 6: 225-232
[139] Boehm DH, Human PA, von Oppell U, et al. Adenosine cardioplegia: reducing reperfusion injury of the ischaemic myocardium. Eur J Cardio-thorac Surg. 1991, 5:542–545
[140] Mentzer RM, Birjiniuk V, Khuri S, et al. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg. 1999, 229: 643–650
[141] Galinanes M, Shattock MJ, Hearse DJ. Effects of potassium channel modulation during global ischemia in isolated rat heartwith and without cardioplegia. Cardiovasc Res. 1992, 26: 1063-1068
[142] Picard S, Crinti A, Iwashiro K, et al. Protection of human myocardium in vitro by KATP activation with low concentrations ofbimakalim. J Cardiovasc Pharmacol. 1999, 34: 162-172
[143]徐长宪,宋惠民、李守先,等.冷浸泡法保存犬心3小时后原位心脏移植的实验研究.中华器官移植杂志. 2000, 21: 331-333
[144] Qayumi AK, mieson WRE, Rosdo LJ, et al. Preservation techniques for heart transplantation. J Heart Lung Transplant. 1991, 10: 518-526
[145] Nutt MP, Fielde BL, Sebree LA, et al. Assessment of function, perfusion, metabolism, and histology in hearts preserved with University of Wisconsin solution. Circulation. l992, 86(Suppl II): 333-342
[146] Sanghong B, Keith L M. Gene therapy for restenosis getting nearer the heart of the matter. Cric Res. 1998, 82: 295-305
[147] Roe BB, Hutohinson NH, Ullgot DJ, et al. Myocardial Delivery of blood cardioplegia. Circulation. 1991, 34(suppl): 380-395
[148]李佳春,李功宋主编.体外循环灌注学.北京:人民军医出版社,1993; 460-466
[149] Stringham JC, Southard JH, Hegge J, et al. Limitations of heart preservation by cold Storage. Transplantation. 1992, 53: 287-294
[150] Drinkwater DC, Rudis E, Laks H, et al. University of Wisconsin solution versus Stanford Cardioplegic solution and the development of cardiac allograft vasculopathy. J Heart Lung Transplant. 1995, 14: 891-896
[151] Demmy TL, Biddle JS, Bennet LE, et al. Organ preservation solutions in heart transplantation-patterns of usage and related survival. Transplatation. 1997, 63: 262-269
[152] Hiroyurry Kohno,Ka Isashiki,Yasutaka Uene,et al. Cold Storage of the rat heart for transplantation. J Thorac Cardiovasc Surgery. 1987, 93: 93-94
[153] Yoshihisa T, Shigeki M, Yoshie O, et al. Inhibition of lipioperoxidation with the lazaroid U74500A attenuates ischemia reperfusion Injury in a canine orthotopic heart transplantation model. J Thorac Cardiovase Surg. 1996, 112: 1024-1031
[154] Collins GM, Wicomb WN. Present Status of kidney preservation for transplantation. J Hear ttransplant. 1983, 2: 94-103
[155] Hendry PJ, Walley VM, Koshal A, et al. Are temperature attained by donor hearts during transport too cold? J Thorac Cardiovasc Surg. 1989, 98: 517-522
[156] Swanson DK, Pasoglu HA. Improved heart preservation with UW preservation solution. J Heart Transplant. 1988, 47: 733-744
[157]张中明,朱立言,曹红.不同Ca2+浓度的St. Thomas停搏液对未成熟心肌的保护作用.徐州医学院学报. 1997,17: 251-254
[158] Paul J, Hendry Frcsc, Rosalind S, et al. A comparison of intraceller solution for donor heart preservation. J Thorac Cardiovase Surg. 1993, 105: 667-672
[159] Sumimoto R, Linden SL, Southerd JH, et al. A comparison of histidine lactobionate and UW solution in 48-hour dog liver preservation. J Transplantation,1992, 54: 610-621
[160] Ingeborg MK, Obermaur RP, Briill T, et al. Comparison of the solutions of Bretshneider, St.Thomas Hospital and the nation institutes of health for cardioplegic protection during moderate hypothemic arrest. J Eur Surg Res. 1998, 30: 243-251
[161] Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg. 2003, 75: 644-664
[162]徐新春,王文健.钙超载与心肌缺血再灌注损伤.心血管病学进展. 2000,21:227-230
[163] Fan H, Sun B, Gu Q, et al. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol 2002, 282: 1778-1786
[164] Schwertz H, Langin T, Platsch H, et al. Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits proteomics. 2002, 2:988-995
[165] Lee YM, Chen HR, Hsiao G. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res 2002. 33: 72-80
[166]赵新.实验性心肌缺血引起的脂质过氧化反应和抗氧化剂的抑制作用.西安医科大学学报. 1987,2: 133-138
[167] Wang QD,Pernow J, Sjoquist P0, et al. Pharmacological Possibilities Res. 2002,55:25-37
[168] Kajstura J,Cheng W, Reiss K,et al. Apoptosis and Necrotic myocyte cell deaths are in rats. Lab Invest. 1996, 74: 86-107
[169] Holleyman CR, Larson DF. Apoptosis in the ischemic reperfused myocardium. Perfusion 2001, 16: 491-502
[170] Sabbah HN,Sharov VG,Goldstein S. Programmed cell death in the progression of heart failure. Ann Med. 1998, 30(Suppl): 33-38
[171] Tomei LD, Umansky SR. Apoptosis and the heart: a brief review. AnnN Y Acad Sci 2001, 946: 160-168
[172] Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury inducse apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994, 94: 1621-1628
[173] Kumar D, Kirshenbaum LA, Li T, et al. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal. 2001, 3: 135-145
[174] Haunstetter A, Izumo S. Toward antiapoptosis as new treatment modality. Circ Res. 2000, 86: 371-376
[175] Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad sci. 1999, 96: 8144-8149
[176] Fliss H. Accelerated apoptosis in reperfused myocardium: friend or foe? Basic Res Cardiol. 1998, 93: 90-93
[177] Fliss H, Gattinger D. Apoptosis in ischemic and reperfused ratmyocardium. Circ Res 1996, 79: 949-956
[178] Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte deaths are independent contributing variables of infarct size in rats. Invest. 1996, 74: 86-107
[179] Scarabelli TM, Knight RA, Rayment NB, et al. Quantitative assessment of cardiac myocyte apoptosis in tissue sections using the fluorescence-basedtunnel technique enhanced with counterstains. J Immunol Methods. 1999, 228: 23-28
[180] Leist M, Nicotera P. The shape of cell death. Biochem Biophys Res. 1997, 236: 1-13
[181] Daemen MA, vant Veer C, Denecker Q et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest. 1999, 104: 541-549
[182] Nossuli TO, Lakshminarayanan V, Baumgarten G et al. Achronic mouse model of myocardial ischemia-reperfusion: essential in cytokine studies. AM J Physiol. 2000, 278: 1049-1055
[183] Bielawska AE, Shapiro JP, Jiang L, et al. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 1997, 151: 1257-1263
[184] Gurevitch J, Frolkis I, Yuhas Y, et al. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol. 1996, 28: 247-252
[185] Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor-alpha induced apoptosis in cardiac myocytes involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996, 98: 2854-2865
[186] FerrariR, Agnoletti L, Comini L, et al. Oxidative stress during myocardial ischemia and heart failure. Euro Heart J 1998, 19: 2-11
[187] Von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999, 99: 2934-2941
[188] Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992, 80: 879-886
[189] Hockenbery DM, Oltvai ZN, Yin XM, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993, 75: 241-251
[190] Misao J, Hayakawa Y, Ohno M, et al. Expression of bcl-2 protein, an inhibitor of Apoptosis, and Bax, an Accelerator of Apoptosis, in Ventricular Myocytes of Human Hearts With Myocardial Infarction. Circulation. 1996, 94: 1506-1512
[191] Green DR. Apoptotic pathways: the roads to ruin. Cell. 1998, 94: 695-698
[192] Zou H, Henzel WJ, Liu X, et al. Apaf-1,a human protein homologous to C. elegans CED-4, participates in cytochromec-dependent activation of caspase-3. Cell. 1997, 90: 405-413
[193] Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J. 1998, 335: 465-480
[194] Long X, Boluyt MO, Hipolito ML, et al. p53 and Hypooxia induced Apoptosis of Cultured Neonatal Rat Cardiac Myocytes. J Clin Invest 1997, 99: 2635-2643
[195] Deiry WS, Tokino VE, Velculescu DB, et al. WAF-1,a potential mediator of p53 tumor sumor suppression. Cell. 1993, 75: 817-825
[2] Follette DM, Steed DL, Foglia RP, Fey KH, Buckberg GD. Reduction of postischemic myocardial damage by maintaining arrest during initial reperfusion. Surg Forum. 1977, 28: 281-283
[3] Beckberg GD. A proposed "solution" to the cardioplegic controversy. J Thorac Cardiovasc Surg 1979, 77: 803-815
[4] Fremes SE, Weisel RD, Mickle DA, Ivanov J, Madonik MM, Seawright SJ, Houle S, McLaughlin PR, Baird RJ Myocardial metabolism and ventricular function following cold potassium cardioplegia. J Thorac Cardiovasc Surg. 1985, 89: 531-546
[5] Demmy TL, Biddle JS, Bennett LE, Walls JT, Schmaltz RA, Curtis JJ. Transplantation. Organ preservation solutions in heart transplantation--patterns of usage and related survival.1997, 63: 262-269
[6] Shriakura R,Matsuda H,Nakata S, et al、Preservation of Cadavar Heart with Belzer UW Solution :24- hour Storage system for asphyxiated canine hearts. J Eur Surg Res. 1990, 22: 197-205
[7] Chambers DJ, Hearse DJ. Cardioplegia and surgical ischemia. Sperelalkis N,Kurachi Y, Terzic A, Cohen MV, eds. Heart physiology and pathophysiology. San Diego: Academic Press. 2001, 887～925
[8] Attwell D, Cohen I, Eisner D, et al. The steady–state TTX-sensitive (window) sodium current in cardiac Purkinje fibres. Pflugers Arch. 1979, 379: 137-142
[9] Bretschneider HJ. Myocardial protection. Thorac Cadiovasc Surg. 1980, 28: 295-302
[10] Houischer M, Groenewoud AF.Current status of the HTK solution of Bretschneider in organ preservation. Transplantation Proceedings. 1991, 23: 2334-2337
[11] Hachida M, Ookado A, Nonoyama M, et al. Effect ofHTK solution for myocardial preservation. J Cardiovasc Surg. 1996, 37: 269-274
[12] Chocron S, Kaili D, Yan Y, Toubin G, Latini L, Clement F, Viel JF, Etievent JP. Intermediate lukewarm (20℃) antegrade intermittent blood cardioplegia compared with cold and warm blood cardioplegia. J Thorac Cardiovasc Surg. 2000, 119: 610-616
[13] Buckberg GD. Oxygenated cardioplegia: blood is a many splendored thing. Ann Thorac Surg. 1990, 50: 175-177
[14] Minatoya K, Okabayashi H, Shimada I, Tanabe A, Nishina T, Nandate K, Kunihiro M.Intermittent antegrade warm blood cardioplegia for CABG: extended interval of cardioplegia.Ann Thorac Surg. 2000, 69: 74-76
[15] Langendorff O. Untersuchungen am uberlebenden saugetierherz. Arch Ges Physiol. 1895, 61: 291-316
[16] Porter WT. A new method for the study of the isolated mammalian heart. Am J Physiol. 1898, 1: 511-517
[17] Legtenberg RJ,Houston RJ,Smits P.Hemodynamic changes caused by glibenclamide in isolated, working, erythrocyte perfused rat heart.Adv Exp Med Biol. 1999, 471: 257-263
[18] Sutherland FJ, Hearse DJ. The isolated blood and perfusion fluid perfused heart. Pharmacol Res. 2000, 41: 613-627
[19] Suzer O, Suzer A, Aykac Z. Direct cardiac effects in isolated perfused rat hearts measured at increasing concentrations of morphine, alfentanil, fentanyl, ketamine, etomidate, thiopentone, midazolam and propofol. Eur Janaesthesiol. 1998,15: 480-485
[20] Hannon J P, Bossone C A, Wade C E. Normal physiological values for conscious pigs used in biomedical research. Lab Anim Sci. 1990, 40: 293-298
[21] Li D, Ren B H, Shen Y, et al. A Swine model for long-term evaluation of prosthetic heart valves. ANZ J Surg, 2007. 77: 654-658
[22] Lomholt M, Nielsen S L, Hansen S B, et al. Differential tension between secondary and primary mitral chordae in an acute in-vivo porcine model. J Heart Valve Dis. 2002, 11: 337-345
[23] Smerup M, Pedersen T F, Nyboe C, et al. A long-term porcine model for evaluation of prosthetic heart valves. Heart Surg Forum. 2004, 7: 259-264
[24] Wittnich C, Belanger M P, Wallen W J, et al. A long-term stable normothermic cardiopulmonary bypass model in neonatal swine. J Surg Res. 2001, 101: 176-182
[25]柳德斌.自体心包在三尖瓣成形手术中的实验研究: [博士学位论文].北京:清华大学医学院,2009
[26] Li D, Ren B H, Shen Y, et al. A Swine model for long-term evaluation of prosthetic heart valves. ANZ J Surg. 2007, 77: 654-658
[27] Duke E. C., Vincent K. H., Wen C., Maceo B. Studies in the physiology of cardiopulmonary bypass using a swine model: Swine as Models in Biomedical Research. Swindle M. M., Moddy D. C., Phillips L. C. Iowa State University Press. 1992:185-197
[28] Hubert M B, Salazkin I, Desjardins J, et al. Cardiopulmonary bypass surgery in swine: a research model. J Exp Anim Sci. 2003, 43: 135-149
[29] Boschert K, Flecknell P A, Fosse R T, et al. Ketamine and its use in the pig. Recommendations of the Consensus meeting on Ketamine Anaesthesia in Pigs, Bergen 1994. Ketamine Consensus Working Group. Lab Anim, 1996, 30(3): 209-219
[30]卿恩明.心血管手术麻醉学.北京:人民军医出版社, 2006:56
[31] Strom J, Haggmark S, Reiz S, et al. Cardiovascular effects of pentobarbital in pigs, and the lack of response to naloxone in pentobarbital induced circulatory failure. Acta Anaesthesiol Scand. 1987, 31: 413-416
[32] Skovsted P, Sapthavichaikul S. The effects of isoflurane on arterial pressure, pulse rate, autonomic nervous activity, and barostatic reflexes. Can Anaesth Soc J. 1977, 24: 304-314
[33] Adams H A. [S-(+)-ketamine. Circulatory interactions during total intravenous anesthesia and analgesia-sedation]. Anaesthesist. 1997, 46: 1081-1087
[34] White P F. The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg. 2002, 94: 577-585
[35]钟佛添,刘初生,巫国勇等.供者心脏热缺血后收缩力、三磷酸腺苷、超微结构的关系.中国胸心血管外科临床杂志.2000,7:28-310
[36] Belzet FO, Southard JH. Principles of solid-organ preservation by cole storage.Transplantation. 1988, 45: 673-675
[37] Weiss M, Piwnica A, Bloch G et al. Experimental evaluation of Celsior, a new heart preservation solution. Eur J Cardiothorac Surg, 1994, 8: 207-213
[38] Bauza G, Lima L, Le Moyec L, Gandjbakhch I, Eugène M. 12-hour preservation of rat hearts with "fabrique d'implants et d'instruments" or University of Wisconsin oxygenated microperfused cardioplegic solution. Transplant Proc. 1996, 28: 2899
[39] Yeh CH, Lin YM, Wu YC, et al. Notric oxide attenuates cardiomyocytic apoptosis via diminished mitochondrialcomplex I up-regulation from cardiac ischemia-reperfusion injury under cardiopulmonary bypass[J]. J Thorac Cardiovasc Surg. 2004, 128: 180
[40] Bouma P, Ferdinandy P, Sipkema P et al. Nitric oxide is an important determinant of coronary flow in the isolated blood perfused rat heart. Basic Res Cardiol. 1992,87: 570-584
[41] Mizuno A, Baretti R, Buckberg GD, et al. Endothelial stunning and myocyte recovery after referfusion of jeopardized muscle: a role of L-arginine blood cardioplegia. J Thorac Cardiovasc Surg. 1997,113: 379
[42] Pabla R, Buda AJ, Flynn DM et al. Nitric oxide attenuates neutrophil mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res.1996, 78: 65-72
[43] Nonami Y. The role of nitric oxide in cardiac ischemia-reperfusion injury. Jpn Circ J. 1997, 61:119-132
[44] Amrani M,Gray CC,Smolenski RT et al. The effect of L-Arginine on myocardial recovery after cardioplegic arrest and ischemia under moderate and deep hypothermia. Circulation, 1997, supple II 96: 274- 279
[45] Kown MH, Lijkwan MA, Jahncke CL, et al. L-Arginine polymers enhance coronary flowand reduce oxidative stress following cardiac transplantation in rats. J Thorac Cardiovasc Surg. 2003, 126: 1065
[46] Pernow J,Uriuda Y,Wang QD et al. The protective effect of L-arginine on myocardial injury and endothelial function following ischaemia and reperfusion in the pig. Eur Heart J.1994,15: 1712-1719
[47] Amrani M, Chester AH,Jayakumar B, et al. L-arginine reverses low coronary reflow and enhances postischaemic recovery of cardiac mechanical function. Cardiovasc Res. 1995, 30: 200-204
[48] Kronon MT, Allen BS,Halldorsson A et al. Dose dependency of L-arginine in neonatal myocardial protection: the nitric oxide paradox. J Thorac Cardiovasc Surg. 1999,118:655-64
[49] Soos P, Andrasi T, Buhmann V, et al. Myocardial protection after systemic application of L- arginine during reperfusion. J Cardiovasc Pharmacol. 2004, 43: 782
[50] Albes M, Baumgartel I, Rohde R et al. Influence of dextrans on cardiac preservation in an extracorporeal rat heart model. Eur Surg Res. 1995, 27: 406-410
[51] Le-Gal YM,Scott T, Prabhakaran VM et al. Heart-lung protection from ischemic injury during 8 hour hypothermic preservation. Acta Biomed Ateneo Parmense. 1994, 65:181-198
[52] Sumimoto R, Linden SL,Southerd JH, et al .A comparison of hiStidine lactobionate and UW solution In 48-hour dog liver preservation. J Transplantation. 1992, 54: 610-621
[53] Gschwend JE,Continuous In situ cold perfusion with HTK solution In nephron spring surgery for renal tumor , J Urology,1997, 156: 1307-1311
[54] Pedro J,Wilson J,Donald GM,et al. The role of cardioplegic solution buffering In myocardial protection. J Thorac Cardiovasc Surg. 1985, 89: 689-699
[55] Wilson GJ,Axford-Gatley RA,Bush BC,et al .European versus North American cardioplehia Comparsion of Bretschmeiders and Roes cardioplegic solutions in a canine model of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990, 38: 4-10
[56] Fedelesova M,Ziegelhoffer A,Krause EC,et al. Effect of exogenous adenosine triphosphate on the metabolic State of the excised hypothemic dog heart. J Circ Res. 1960, 24: 617-627
[57]郭为农,吾柏铭.腺苷的心血管病生理作用及其临床应用.国外医学心血管分册. 1993,20: 91-94
[58] Lee HT, Emala CW. Characterization of adenosine receptors in human kidney proximal tubule (HK-2) cells. Exp Nephrol. 2002, 10: 383-392
[59] Mangoni ME, Barrere-Lemaire S. Adenosine receptors, heart rate, and cardioprotection. Cardiovasc Res. 2004, 62: 447-449
[60] Janin Y, Qian YZ, Hoag JB, et al. Pharmacologic preconditioning with monophosphoryl lipid A is abolished by 5-hydroxydecanoate, a specific inhibitor of the K(ATP) channel. J Cardiovasc Pharmacol. 1998, 32: 337-342
[61] Spinale FG. Cellular and molecular therapeutic targets for treatment of contractile dysfunction after cardioplegic arrest. Ann Thorac Surg. 1999, 68: 1934-1938
[62] Dobson GP, Jones MW. Adenosine and lidocaine: A new concept in nondepolarizing surgical myocardial arrest, protection, and preservation. J Thorac Cardiovasc Surg. 2004, 127: 794-797.
[63] De Jong JW,Meer P,Loon H, et al. Adenosisne as an adjunct to potassitum cardioplegia:effect on function,energy metabolism,and electrophysiology. J Thora Cardiovasc Surg. 1990,100: 445-454
[64] Dowey JM,Liu CS,Thornton JD. Adinosine and anti-infarct effects of preconditioning. J Cardiovasc Res. 1993, 27: 3-8
[65] Boudjema K, Vanfulik TM,Lindell SL, et al. Effect of oxidized and reduced glutathione in heart preservation. J Transplantation ,1990, 50: 948-952
[66]马欣,李玉成.谷氨酰胺与心肌缺血再灌注损伤.中国动脉硬化杂志. 2007,15: 873-875
[67] Westagy S. Organ dysfunction after cardiopulmonary bypass: a systemic inflammatory reaction initiated by the extracorporeal cricuit. 1987, 13:89-95
[68] Khogali SE.Harper AA.Lyall JA.Rennie MJ Effects of L-glutamine on post-ischaemic cardiac function:protection and rescue 1998, 30: 819-827
[69] Stottrup NB.Kristiansen SB.Lofgren B.Hansen BF Kimose HH Botker HE L-gluta-mate and glutamine improve haemodynamic function and restore myocardial glycogen content during postischaemic reperfusion:A radiactive tracer study in the rat isolated beart 2006, 30: 1099-1103
[70] Liu J, Marchase RB, Chatham JC. Glutamine-induced protection of isolated rat beart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protedin O-GlcNAc levels. 2007, 43:177-185
[71] Ingeborg R, Kober M, Obermaur RP, et al. Comparison of the solutions ofBretshneider,St.Thomas’Hospital and the national institutes of health for cardioplegic protection during moderate hypothermic arrest. Eur Surg Res. 1998, 30:243-251
[72] Hacida M, Ookado A, Nonoyama M, et al. Effect of HTK solution for myocardial preservation. J Cardiovasc Surg. 1996, 37:269-274
[73] Murphy E.Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. CircRes, 2004, 94: 7-14
[74] Garlid K D,Paucek P.Yarov-arovoy T, et a1.Cardioprotective effect of diazoxide and itsinteraction with mitochondrial ATP-sensitive K+ channels.CircRes. 1997, 8l: 1072-1079
[75] Holmuhamedov EL, Wang L, Terzic A. ATP-sensitive K+channel openers prevent Ca2+ overload in rat cardiac mitochondria. J Physiol. 1999, 519: 347-360
[76] Laclau MN, Boudina S, Thambo JB, et al. Cardioprotection by ischemic preconditioning preserves mitochondrial function and functional coupling between adenine nucleotide translocase and creatinekinase. J Mol Cell Cardiol. 2001, 33: 947-956
[77] Babcock DF, Herrington J, Goodwin PC, et al. Mitochondrial participation in the intracellular Ca2+ network. J Cell Biol. 1997, 136: 833-844
[78] Ozcan C, Bienengraeber M, Petras P, et al. Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress atreoxygenation. Am J Physiol Heart Circ Physiol. 2002, 282: 531-539
[79] Wang Y, Ashraf M. Role of protein kinase C in mitochondrial KATP channel mediated protection against Ca2+ overload injury in rat myocardium. Circ Res. 1999, 84: 1156-1165
[80] Halestrap AP. Regulation of mitochondrial metabolism through changes in matrix volume. Biochem Soc Trans. 1994, 22: 522-529
[81]兰锡纯,冯卓荣等.心脏血管外科学.北京:人民卫生出版社,2002.422
[82]杭燕南,庄心良,蒋豪,徐慧芳等.当代麻醉学.上海:上海科学技术出版社,2002:484
[83] Hosenpud JD, Bennett LE, Keck BM, et al. The registry of the International Society for Heart and Lung Transplantation: sixteenth official report. J Heart Lung Transplant. 1999, 18: 611-626
[84]孙晨光,夏求明,等.异体原位心脏移植(附6例报道).中华器官移植杂志. 2000, 21: 237-239
[85] J.Wei, C.Y Chang, Y C Chuang, et al. Successful Heart Transplantation After 13 Hours of Donor Heart. Transplantation Proceedings. 2005, 37: 2253-2254
[86] Wheeldon D. Thoracic organ preservation. Perfusion. 1991, 6: 191-202
[87] Wahlers T, Cremer J, Fleguth HC, et al. Dornor related variables and 30-day mortality after heart transplantation. J Heart Lung Transplant. 1991, 10: 22-27
[88] Del Rizzo DF, Menkis AH, Pfungfelder PW, et al. The role of donor age and ischemic time on survival following orthotopic heart transplantation. J Heart Lung Transplant. 1999, 18: 310-319
[89] Young JB, Naftel DC, Bourge RC, et al. Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multinstitutional report. The transplant cardiologists research Database Group. J Heart Lung Transplant. 1994, 13: 353-365
[90] Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretrasnplantation risk factors for death after heart transplantation: a multi-institutional study. The transplant cardiologistsresearch Database Group. J Heart Lung Transplant. 1993, 12: 549-562
[91] Fernandez J, Aranda J, Mabbot S, et al. Overseas procurement of donor hearts: ischemic time effect of postoperative outcomes. Transplant Proc. 2001, 33: 3803-3804
[92] Brigand EM, Bergin PJ, Rosenfelt FL, et al. Successful long-term outcome with prolonged ischemic in cardiac allografts. J Heart Lung Transplant. 1995, 14: 845-940
[93] Jahania MS, Sanchez JA, Narayan P, et al. Heart preservation for transplation principles and strategies. Ann Thorac Surg. 1999. 68: 1983-1987
[94] Buckberg GD. Update on current techniques of myocardial protection. Ann Thorac Surg. 1995. 60: 805-814
[95] Menasche PF, Groussect C, Peynet J, et al. Improved recovery of heart transplants with a specific kit of preservation solution. J Thorac Cardiovasc Surg. 1993. 105: 353-363
[96] Kevelaitis E, Peynet J, Mousa C, et al. Preconditioning by mitochondria ATP-sensentive potassium channel opener: an effective approach for improving the preservation of heart transplants. Circulation. 1999. 100(19 Supplement):345-350
[97] Shyu KG, Kuan PL, Cheng JJ, et al. Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting. Am Heart J. 1998, 135: 862-870
[98] Kawahto K, Mohara J, Misawa Y, et al. Assessment of the myocardial protective effect of antegrade warm blood cardioplegia by measuring the release of biochemical markers. Surg-Today. 1999, 29: 322-329
[99] Klaver MJ, Buckingham MG, Rich GF. Lidocaine attenuates cytokine-induced cell injury in endothelial and vascular smooth muscle cells. Anesth Analg. 2003, 97: 465-470
[100] Klaver MJ, Buckingham MG, Rich GF. Isoflurane pretreatment has immediate anddelayed protective effects against cytokine-induced injury in endothelial and vascularsmooth muscle cells.Anesthesiology. 2003, 99: 896-903
[101] Lopez JR , Jahangir R , Jahangir A , et al.Potassium channel openers prevent potassium-induced calciumloading of cardiac cells:possible implications in cardioplegia.J Thorac Cardiovasc Surg.1996;112:820–31.
[102] Plachinta RV, de Klaver MJ, Hayes JK, et al.The protective effect of protein kinase C and adenosine triphosphate-sensitive potassium channel agonists against inflammation in rat endothelium and vascular smooth muscle in vitro and in vivo.Anesth Analg. 2004;99:556-61
[103]王翠梅,曹红,戴体俊.线粒体敏感性ATP钾通道不参与异丙酚预处理的心肌保护.中国药理学通报2003,19(10):1155-9
[104] Beresewicz A,Maczewski M,Duda M. Effect of classic preconditioning and diazoxide on endothelial function and O2- and NO generation in the post-ischemic guinea-pig heart.Cardiovascular Research. 2004, 63, 118-129
[105] Cohen NM,Wises RM,Wechsler AS,et al. Elective cardiac arrest with a hyperpolarizing adenosine triphosphate-sensitive potassium channel opener. J ThoracCardiovasc Surg. 1993, 106: 317-328
[106] Lawton JS, Harrington GC, Allen CT, et al. Myocardial protection with pinacidil cardioplegia in the blood-perfused heart. Ann Thorac Surg.1996, 61: 1680–1688
[107] Lawton JS,Hsia PW,Allen CT,et al.Myocardial protection in the acutely injured heart: hyperpolarizing versus depolarizing hypothermic cardioplegia. J Thorac CardiovascSurg. 1997, 113: 567–575
[108] Jilkina O, Kuzio B, Grover GJ, et al. Sarcolemmal and mitochondrial effects of a KATP opener, P-1075, in"polarized" and "depolarized" Langendorff-perfused rat hearts. Biochim Biophys Acta. 2003, 8: 39-50
[109] Jiang C, Mochizuki S, Poole-Wilson PA, et al. Effect of lemakalim on action potentials, intracellular calcium, and contraction in guinea pig and human cardiac myocytes. Cardiovasc Res. 1994, 28: 851–857
[110] Garlid KD, Paucek P, Yarov-Yarovoy V, et al. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+channels. : Possible mechanism of cardioprotection. Circ Res. 1997, 81: 1072-1082
[111]张凯伦,杨运海,胡志伟等.含二氮嗪停搏液对豚鼠心肌电生理的影响.中华胸心血管外科杂志. 2004,20:44-46
[112] Kajstura J, Cheng W, Reiss K,et al. Apoptosis and Necrotic myocyte cell deaths are in rats. Lab Invest. 1996, 74: 86-107
[113] Freude B, Masters TN, Robicsek F, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol, 2000, 32: 197-208
[114] McCully JD, Wakiyama H, Cowan DB, et al. Diazoxide amelioration of myocardial injury and mitochondrial damage during cardiac surgery. Ann Thorac Surg. 2002, 74: 2138-2146
[115] Oltvai Z N, Milliman C L, Korsmeyer S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993, 74: 609 - 619
[116] Ichinose M, Yonemochi H, Sato T, et al. Diazoxide triggers cardioprotection against apoptosis induced by oxidative stress. Am J Physiol. 2003, 284: 2235-2241
[117] Akao M, Ohler A, OpRourke B, et al. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res. 2001, 88: 1267-1275
[118] Daugas E , Susin SA , Zamzami N , et al. Mitochondrio2nuclear translocation of AIF in apoptosis and necrosis. FASEB J. 2000, 14: 729-739
[119] Sperelakis N, Sunagawa M, Nakamura M. Electrogenesis of the resting potential. Heartphysiology and pathophysiology. San Diego: Academic Press, 2001: 175-198
[120] Opie LH. Channels, pumps, and exchangers. The heart: physiology and metabolism. New York: Raven Press, 1991: 67-101
[121] Sperelalkis N, Kurachi Y, Terzic A, Cohen MV. Heart physiology and pathophysiology. San Diego: Academic Press, 2001, 887-925
[122] Attwell D, Cohen I, Eisner D, et al. The steady–state TTX-sensitive (window) sodium current in cardiac Purkinje fibres. Pflugers Arch, 1979, 379: 137-142
[123] Snabaitis AK, Chambers DJ. Long-term myocardial preservation: beneficial and additive effects of polarized arrest (Na+-channel blockade), Na+/H+-exchange inhibition, and Na+/K+-cotransport inhibition combined with calciumdesensitization. Transplation. 1999, 68: 1444-1453
[124] Walgama OV, Shattock MJ, Chambers DJ. Myocardial arrest and protection: dual effect of a K-channel opener and Na-channel blocker as an alternative to hyperkalemia. J Mol Cell Cardiol. 2000, 32: 41-53
[125] Snabaitis AK, Shattock MJ, Chambers DJ. Comparison of polarized and depolarizedarrest in the isolated rat heart for long-term preservation. Circulation. 1997, 96: 3148-3156
[126] Cohen NM, Wises RM, Wechsler AS, et al. Elective cardiac arrest with a hyperpolarizing adenosine triphosphate-sensitive potassium channel opener. J Thorac Cardiovasc Surg. 1993,106: 317-328
[127] Jiang C, Mochizuki S, Poole-Wilson PA, et al. Effect of lemakalim on action potentials intracellular calcium, and contraction in guinea pig and human cardiac myocytes. Cardiovasc Res. 1994, 28: 851–857
[128] Dorman BH, Hebbar L, Hinton RB, et al. Preservation of myocyte contractile function after hypothermic cardioplegic arrest by activation of ATP-sensitive potassium channels. Circulation. 1997, 96: 2376-2384
[129] Dorman BH, Hebbar L, Clair MJ, et al. Potassium channel opener augmented cardioplegia: protection of myocyte contractility with chronic left ventricular dysfunction. Circulation.1997, 96: 253-2259
[130] Sugimoto S, Puddu PE, Monti FF, et al. Pretreatment with the adenosine triphosphate-sensitive potassium channel opener nicorandil and improved myocardial protection during high potassium cardioplegic hypoxia. J Thorac Cardiovasc Surg,1994, 108: 455-466
[131] Walgama OV, Shattock MJ, Chambers DJ. Efficacy of a KATP channel opener to induce myocardial arrest: species differences. J Mol Cell Cardiol. 2000, 32: A40-41
[132] Galinanes M, Shattock MJ, Hearse DJ. Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia. Cardiovasc Res.1992, 26: 1063–1068
[133] He GW. Coronary endothelial function in open heart surgery. Clin Exp Pharmacol Physiol. 1997, 24: 955-957
[134] He GW. Potassium channel opener in cardioplegia may restore coronary endothelial function. Ann Thorac Surg. 1998, 66: 1318-1322
[135] Holmuhamedov EL, Jovanovic S, Dzeja PP, et al. Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function. Am J Physiol. 1998, 275: H1567-1576
[136] Baines CP, Liu GS, Birincioglu M, et al. Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. Am J Physiol. 1999, 276: H1361-1368
[137] Toyoda Y, Levitsky S, McCully JD. Opening of mitochondrial ATP-sensitive potassium channels enhances cardioplegicprotection. Ann Thorac Surg. 2001, 71: 1281-1289
[138] Pieper GM, Gross GJ. Anti-free-radical and neutrophil-modulating properties of nitrovasoditator, nicorandil. Cardiovase Drugs Ther. 1992, 6: 225-232
[139] Boehm DH, Human PA, von Oppell U, et al. Adenosine cardioplegia: reducing reperfusion injury of the ischaemic myocardium. Eur J Cardio-thorac Surg. 1991, 5:542–545
[140] Mentzer RM, Birjiniuk V, Khuri S, et al. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg. 1999, 229: 643–650
[141] Galinanes M, Shattock MJ, Hearse DJ. Effects of potassium channel modulation during global ischemia in isolated rat heartwith and without cardioplegia. Cardiovasc Res. 1992, 26: 1063-1068
[142] Picard S, Crinti A, Iwashiro K, et al. Protection of human myocardium in vitro by KATP activation with low concentrations ofbimakalim. J Cardiovasc Pharmacol. 1999, 34: 162-172
[143]徐长宪,宋惠民、李守先,等.冷浸泡法保存犬心3小时后原位心脏移植的实验研究.中华器官移植杂志. 2000, 21: 331-333
[144] Qayumi AK, mieson WRE, Rosdo LJ, et al. Preservation techniques for heart transplantation. J Heart Lung Transplant. 1991, 10: 518-526
[145] Nutt MP, Fielde BL, Sebree LA, et al. Assessment of function, perfusion, metabolism, and histology in hearts preserved with University of Wisconsin solution. Circulation. l992, 86(Suppl II): 333-342
[146] Sanghong B, Keith L M. Gene therapy for restenosis getting nearer the heart of the matter. Cric Res. 1998, 82: 295-305
[147] Roe BB, Hutohinson NH, Ullgot DJ, et al. Myocardial Delivery of blood cardioplegia. Circulation. 1991, 34(suppl): 380-395
[148]李佳春,李功宋主编.体外循环灌注学.北京:人民军医出版社,1993; 460-466
[149] Stringham JC, Southard JH, Hegge J, et al. Limitations of heart preservation by cold Storage. Transplantation. 1992, 53: 287-294
[150] Drinkwater DC, Rudis E, Laks H, et al. University of Wisconsin solution versus Stanford Cardioplegic solution and the development of cardiac allograft vasculopathy. J Heart Lung Transplant. 1995, 14: 891-896
[151] Demmy TL, Biddle JS, Bennet LE, et al. Organ preservation solutions in heart transplantation-patterns of usage and related survival. Transplatation. 1997, 63: 262-269
[152] Hiroyurry Kohno,Ka Isashiki,Yasutaka Uene,et al. Cold Storage of the rat heart for transplantation. J Thorac Cardiovasc Surgery. 1987, 93: 93-94
[153] Yoshihisa T, Shigeki M, Yoshie O, et al. Inhibition of lipioperoxidation with the lazaroid U74500A attenuates ischemia reperfusion Injury in a canine orthotopic heart transplantation model. J Thorac Cardiovase Surg. 1996, 112: 1024-1031
[154] Collins GM, Wicomb WN. Present Status of kidney preservation for transplantation. J Hear ttransplant. 1983, 2: 94-103
[155] Hendry PJ, Walley VM, Koshal A, et al. Are temperature attained by donor hearts during transport too cold? J Thorac Cardiovasc Surg. 1989, 98: 517-522
[156] Swanson DK, Pasoglu HA. Improved heart preservation with UW preservation solution. J Heart Transplant. 1988, 47: 733-744
[157]张中明,朱立言,曹红.不同Ca2+浓度的St. Thomas停搏液对未成熟心肌的保护作用.徐州医学院学报. 1997,17: 251-254
[158] Paul J, Hendry Frcsc, Rosalind S, et al. A comparison of intraceller solution for donor heart preservation. J Thorac Cardiovase Surg. 1993, 105: 667-672
[159] Sumimoto R, Linden SL, Southerd JH, et al. A comparison of histidine lactobionate and UW solution in 48-hour dog liver preservation. J Transplantation,1992, 54: 610-621
[160] Ingeborg MK, Obermaur RP, Briill T, et al. Comparison of the solutions of Bretshneider, St.Thomas Hospital and the nation institutes of health for cardioplegic protection during moderate hypothemic arrest. J Eur Surg Res. 1998, 30: 243-251
[161] Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg. 2003, 75: 644-664
[162]徐新春,王文健.钙超载与心肌缺血再灌注损伤.心血管病学进展. 2000,21:227-230
[163] Fan H, Sun B, Gu Q, et al. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol 2002, 282: 1778-1786
[164] Schwertz H, Langin T, Platsch H, et al. Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits proteomics. 2002, 2:988-995
[165] Lee YM, Chen HR, Hsiao G. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res 2002. 33: 72-80
[166]赵新.实验性心肌缺血引起的脂质过氧化反应和抗氧化剂的抑制作用.西安医科大学学报. 1987,2: 133-138
[167] Wang QD,Pernow J, Sjoquist P0, et al. Pharmacological Possibilities Res. 2002,55:25-37
[168] Kajstura J,Cheng W, Reiss K,et al. Apoptosis and Necrotic myocyte cell deaths are in rats. Lab Invest. 1996, 74: 86-107
[169] Holleyman CR, Larson DF. Apoptosis in the ischemic reperfused myocardium. Perfusion 2001, 16: 491-502
[170] Sabbah HN,Sharov VG,Goldstein S. Programmed cell death in the progression of heart failure. Ann Med. 1998, 30(Suppl): 33-38
[171] Tomei LD, Umansky SR. Apoptosis and the heart: a brief review. AnnN Y Acad Sci 2001, 946: 160-168
[172] Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury inducse apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994, 94: 1621-1628
[173] Kumar D, Kirshenbaum LA, Li T, et al. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal. 2001, 3: 135-145
[174] Haunstetter A, Izumo S. Toward antiapoptosis as new treatment modality. Circ Res. 2000, 86: 371-376
[175] Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad sci. 1999, 96: 8144-8149
[176] Fliss H. Accelerated apoptosis in reperfused myocardium: friend or foe? Basic Res Cardiol. 1998, 93: 90-93
[177] Fliss H, Gattinger D. Apoptosis in ischemic and reperfused ratmyocardium. Circ Res 1996, 79: 949-956
[178] Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte deaths are independent contributing variables of infarct size in rats. Invest. 1996, 74: 86-107
[179] Scarabelli TM, Knight RA, Rayment NB, et al. Quantitative assessment of cardiac myocyte apoptosis in tissue sections using the fluorescence-basedtunnel technique enhanced with counterstains. J Immunol Methods. 1999, 228: 23-28
[180] Leist M, Nicotera P. The shape of cell death. Biochem Biophys Res. 1997, 236: 1-13
[181] Daemen MA, vant Veer C, Denecker Q et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest. 1999, 104: 541-549
[182] Nossuli TO, Lakshminarayanan V, Baumgarten G et al. Achronic mouse model of myocardial ischemia-reperfusion: essential in cytokine studies. AM J Physiol. 2000, 278: 1049-1055
[183] Bielawska AE, Shapiro JP, Jiang L, et al. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 1997, 151: 1257-1263
[184] Gurevitch J, Frolkis I, Yuhas Y, et al. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol. 1996, 28: 247-252
[185] Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor-alpha induced apoptosis in cardiac myocytes involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996, 98: 2854-2865
[186] FerrariR, Agnoletti L, Comini L, et al. Oxidative stress during myocardial ischemia and heart failure. Euro Heart J 1998, 19: 2-11
[187] Von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999, 99: 2934-2941
[188] Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992, 80: 879-886
[189] Hockenbery DM, Oltvai ZN, Yin XM, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993, 75: 241-251
[190] Misao J, Hayakawa Y, Ohno M, et al. Expression of bcl-2 protein, an inhibitor of Apoptosis, and Bax, an Accelerator of Apoptosis, in Ventricular Myocytes of Human Hearts With Myocardial Infarction. Circulation. 1996, 94: 1506-1512
[191] Green DR. Apoptotic pathways: the roads to ruin. Cell. 1998, 94: 695-698
[192] Zou H, Henzel WJ, Liu X, et al. Apaf-1,a human protein homologous to C. elegans CED-4, participates in cytochromec-dependent activation of caspase-3. Cell. 1997, 90: 405-413
[193] Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J. 1998, 335: 465-480
[194] Long X, Boluyt MO, Hipolito ML, et al. p53 and Hypooxia induced Apoptosis of Cultured Neonatal Rat Cardiac Myocytes. J Clin Invest 1997, 99: 2635-2643
[195] Deiry WS, Tokino VE, Velculescu DB, et al. WAF-1,a potential mediator of p53 tumor sumor suppression. Cell. 1993, 75: 817-825